Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia



Status:Completed
Conditions:Cognitive Studies, Schizophrenia, Psychiatric
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:18 - 65
Updated:5/3/2014
Start Date:February 2009
End Date:August 2013
Contact:Ashley M Schnakenberg, B.S.
Email:ashley.schnakenberg@yale.edu
Phone:203-932-5711

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Cannabinoid Receptor Antagonist Treatment of Cognitive Dysfunction in Schizophrenia

This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing
cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients
diagnosed with schizophrenia.


Inclusion Criteria:

- Schizophrenia or Schizoaffective disorder (DSM-IV SCID-confirmed),

Exclusion Criteria:

- Women who are pregnant, nursing or unwilling to use appropriate birth control
measures during study participation.
We found this trial at
1
site
Yale University
New Haven, Connecticut 6520
(203) 432-4771
Yale University Yale's roots can be traced back to the 1640s, when colonial clergymen led...
?
mi
from
New Haven, CT
Click here to add this to my saved trials